Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 676 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 676 shares of Akero Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $30,338.88. Following the completion of the transaction, the chief financial officer now directly owns 61,959 shares in the company, valued at $2,780,719.92. This represents a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Akero Therapeutics Stock Performance

AKRO stock opened at $44.15 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock has a market cap of $3.52 billion, a P/E ratio of -11.77 and a beta of -0.19. The firm has a 50 day simple moving average of $42.10 and a 200 day simple moving average of $33.79. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AKRO shares. UBS Group lifted their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. HC Wainwright lifted their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Citigroup raised their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $76.29.

Institutional Trading of Akero Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in Akero Therapeutics in the fourth quarter valued at approximately $41,000. Sterling Capital Management LLC lifted its stake in Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after acquiring an additional 1,582 shares during the last quarter. Quarry LP acquired a new stake in Akero Therapeutics in the fourth quarter valued at approximately $83,000. Summit Investment Advisors Inc. lifted its stake in Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after acquiring an additional 450 shares during the last quarter. Finally, Summit Financial Wealth Advisors LLC acquired a new stake in Akero Therapeutics in the third quarter valued at approximately $205,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.